The genome war : how Craig Venter tried to capture the code of life and save the world / James Shreeve
Material type: TextPublication details: New York : Alfred A. Knopf , c2004.Description: x, 403 p. ; 25 cmISBN:- 9780345433749
- 575.1 SHR
- QH431 .S5577 2004
Item type | Current library | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|
Libro - Monografía | Biblioteca Pública de San Miguel de Allende, A.C. | 575.1 SHR (Browse shelf(Opens below)) | Available | 066886 |
Browsing Biblioteca Pública de San Miguel de Allende, A.C. shelves Close shelf browser (Hides shelf browser)
Includes bibliographical references and index.
In May 1998, biologist Craig Venter announced that he was founding a company, Celera, that would sequence the genome by 2001, scooping the government's Human Genome Project by four years. This inflammatory announcement sparked a race that was as much about scientific ego and public recognition as about unlocking the so-called book of life. Shreeve focuses on the tensions between academia and industry, and the rancor that ensued when Venter, who had previously headed a nonprofit research institute, changed camps. The synthesis of business and science posed new questions: can one patent the entire genome? if so, is protection of intellectual property antithetical to the advance of science? Industry is controlled by the bottom line; academia is chained to the politicians who control funding. Both models must battle a public that doesn't understand the intricacies of the research. Add to this the race to make one of the ultimate discoveries, and you get a mudslinging battle of egos. To back this up, Shreeve gives a healthy dose of the molecular biology involved in clear and vivid terms. He gives readers a fly-on-the-wall view of the scientific posturing and agonizing work behind the revelation of the genome's sequence. Shreeve is more concerned with providing a good yarn than answering the questions these events provokes, and the narrative meanders at times, but it gives a compelling look at the politics and business interests that drive science.
There are no comments on this title.